Your browser doesn't support javascript.
loading
Meta-análise Cochrane: teicoplanina versus vancomicina para infecções suspeitas ou confirmadas / Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection
Bugano, Diogo Diniz Gomes; Cavalcanti, Alexandre Biasi; Gonçalves, Anderson Roman; Almeida, Claudia Salvini de; Silva, Eliézer.
  • Bugano, Diogo Diniz Gomes; Universidade de São Paulo. Hospital das Clínicas. São Paulo. BR
  • Cavalcanti, Alexandre Biasi; Hospital do Coração. Instituto de Ensino e Pesquisa. São Paulo. BR
  • Gonçalves, Anderson Roman; Universidade da Região de Joinville. Departamento de Medicina. Joinville. BR
  • Almeida, Claudia Salvini de; Universidade de São Paulo. Hospital das Clínicas. São Paulo. BR
  • Silva, Eliézer; Hospital Israelita Albert Einstein. Unidade de Terapia Intensiva. São Paulo. BR
Einstein (Säo Paulo) ; 9(3)july-sept. 2011. tab, ilus
Article Dans Anglais, Portugais | LILACS | ID: lil-604947
RESUMO

Objective:

To compare efficacy and safety of vancomycin versus teicoplanin in patients with proven or suspected infection.

Methods:

Data Sources Cochrane Renal Group's Specialized Register, CENTRAL, MEDLINE, EMBASE, nephrology textbooks and review articles. Inclusion criteria Randomized controlled trials in any language comparing teicoplanin to vancomycin for patients with proven or suspected infection. Data extraction Two authors independently evaluated methodological quality and extracted data. Study investigators were contacted for unpublished information. A random effect model was used to estimate the pooled risk ratio (RR) with 95% confidence interval (CI).

Results:

A total of 24 studies (2,610 patients) were included. The drugs had similar rates of clinical cure (RR 1.03; 95%CI 0.98-1.08), microbiological cure (RR 0.98; 95%CI 0.93-1.03) and mortality (RR 1.02; 95%CI 0.79-1.30). Teicoplanin had lower rates of skin rash (RR 0.57; 95%CI 0.35-0.92), red man syndrome (RR 0.21; 95%CI 0.08-0.59) and total adverse events (RR 0.73; 95%CI 0.53-1.00). Teicoplanin reduced the risk of nephrotoxicity (RR 0.66; 95%CI 0.48-0.90). This effect was consistent for patients receiving aminoglycosides (RR 0.51; 95%CI 0.30-0.88) or having vancomycin doses corrected by serum levels (RR 0.22; 95%CI 0.10-0.52). There were no cases of acute kidney injury needing dialysis.

Limitations:

Studies lacked a standardized definition for nephrotoxicity.

Conclusions:

Teicoplanin and vancomycin are equally effective; however the incidence of nephrotoxicity and other adverse events was lower with teicoplanin. It may be reasonable to consider teicoplanin for patients at higher risk for acute kidney injury.
Sujets)

Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Vancomycine / Téicoplanine / Toxidermies / Rein / Antibactériens Type d'étude: Essai clinique contrôlé / Etude diagnostique / Étude pronostique / Revues systématiques évaluées langue: Anglais / Portugais Texte intégral: Einstein (Säo Paulo) Thème du journal: Médicament Année: 2011 Type: Article Pays d'affiliation: Brésil Institution/Pays d'affiliation: Hospital Israelita Albert Einstein/BR / Hospital do Coração/BR / Universidade da Região de Joinville/BR / Universidade de São Paulo/BR

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Vancomycine / Téicoplanine / Toxidermies / Rein / Antibactériens Type d'étude: Essai clinique contrôlé / Etude diagnostique / Étude pronostique / Revues systématiques évaluées langue: Anglais / Portugais Texte intégral: Einstein (Säo Paulo) Thème du journal: Médicament Année: 2011 Type: Article Pays d'affiliation: Brésil Institution/Pays d'affiliation: Hospital Israelita Albert Einstein/BR / Hospital do Coração/BR / Universidade da Região de Joinville/BR / Universidade de São Paulo/BR